SCYNEXIS Inc (SCYX) Stock Analysis
Verdict: BUY
Up to $214M non-dilutive BARDA funding de-risks SCY-247 development, but clinical execution and FDA trial hurdles remain key swing factors.
Investment score: 66/100
Analysis as of
Is SCYNEXIS Inc stock worth reviewing? The TradeMates thesis
SCYNEXIS represents a high-upside micro-cap biotech whose primary funding overhang has been neutralized by an up to $214M BARDA award, providing ample runway for clinical development at a deeply discounted price-to-book valuation.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 75/100 (weight 15%)
- Technical Momentum: 68/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 72/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 62/100 (weight 15%)
SCYNEXIS Inc opportunities and risks
What speaks for SCYX
- Transformative BARDA Contract Provides Up to $214M Non-Dilutive Capital
What speaks against SCYX
- Clinical Trial and Regulatory Execution Failure
Peers and competitors
- TLPH
- HYPD
- PLTH.CN
- ODTC
- IMA
- BSEM
- IBO
- LONA
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SCYX | n/a | 1.7x | n/a | 100.0% | -53.3% | -41.3% |
| TLPH | n/a | 58646.5x | n/a | 100.0% | -1507600.0% | -20.9% |
| HYPD | n/a | 40.4x | n/a | 78.4% | 474.9% | -94.6% |
| PLTH.CN | n/a | 0.4x | n/a | 41.0% | -66.9% | -26.8% |
| ODTC | 3227.6x | 0.0x | 846.2x | 0.0% | 0.0% | 0.1% |
| IMA | n/a | 0.0x | 0.8x | 0.0% | 0.0% | -111.3% |
| Peer median | n/a | 0.4x | n/a | 41.0% | 0.0% | -26.8% |
Frequently asked questions about SCYNEXIS Inc (SCYX)
Is SCYX stock a good investment?
The TradeMates model rates SCYNEXIS Inc as BUY with an investment score of 66/100. SCYNEXIS represents a high-upside micro-cap biotech whose primary funding overhang has been neutralized by an up to $214M BARDA award, providing ample runway for clinical development at a deeply discounted price-to-book valuation. This is algorithmic model output, not personal investment advice.
Is SCYX stock a buy?
The TradeMates model verdict for SCYX is BUY with an investment score of 66/100. Treat this as a model signal to review, not a personal buy recommendation.